Sector News

Bristol-Myers’ rumored activists ‘haven’t made a decision’ on the company yet: Starboard CEO

February 7, 2019
Life sciences

Activist hedge fund Starboard Value is “certainly interested in the story at Bristol-Myers,” according to its leader. But that doesn’t mean it’s getting involved.

As Starboard’s CEO, Jeff Smith, told CNBC on Tuesday, Bristol-Myers Squibb “might fit” the profile of a company on which Starboard thinks it can have a positive impact. But “it might not fit that profile. We haven’t made that decision,” he said.

The comments come after a Monday Bloomberg report that the proxy brawler had already picked up a stake in BMS. In response, analysts surmised that Starboard may be looking to thwart the New Jersey drugmaker’s $74 billion deal agreement for Celgene, perhaps by getting another pharma giant to buy Bristol.

Still, they expressed doubts around that idea—in part because the list of pharma players who could actually swallow BMS is short, not to mention unwilling.

AbbVie, Pfizer and Novartis could potentially pull it off, “but all these would require a lot of synergies to be accretive,” Bloomberg Intelligence’s Sam Fazeli told the news service, with Credit Suisse’s Vamil Divan adding in a note to clients that, “We would be surprised if activists are successful in pushing for a larger change.”

As CNBC’s David Faber noted, Starboard also currently has its hands full meddling in other companies, such as pizza chain Papa John’s.

Starboard has “so many different things going on, to take a significant stake where they would actually argue against a deal—who knows,” he said Monday. He also pointed to last year’s deal pact between United Technologies Corporation and Rockwell Collins, reminding viewers of then-rumors that Starboard could pick up a stake and argue against that deal. “Nothing ever came of it,” he said.

By Carly Helfand

Source: Fierce Pharma

Related News

May 28, 2020

Thermo Fisher continues global expansion push with CSL Behring biologics plant lease

Life sciences

Thermo Fisher Scientific has aggressively expanded its biologics manufacturing capacity in recent months, dumping millions into capital spending. Now, in another deal that will keep its supply chain growing, Thermo […]

May 28, 2020

Siemens begins shipping coronavirus antibody tests with goal of 50M per month

Life sciences

While aiming to double its manufacturing capacity to more than 50 million blood tests per month, Siemens Healthineers has begun shipping its COVID-19 serology kits internationally, for use on about […]

May 26, 2020

Sanofi to sell stake in Regeneron

Life sciences

Sanofi has revealed its intent to sell its equity investment in Regeneron through a registered public offering and related share repurchase by the firm. The French drugmaker currently holds around […]